Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Progyny ( (PGNY) ) has provided an update.
Progyny, Inc. announced that the employment of its President, Michael Sturmer, will end on December 31, 2025. While the company expressed gratitude for Mr. Sturmer’s contributions over the past five years, it will not appoint a successor as it has strengthened its executive leadership team with several key appointments in recent years. To maintain continuity on strategic initiatives, Mr. Sturmer will serve as a consultant for Progyny until December 31, 2026, under a new agreement entitling him to an advisory fee and adjusted options benefits.
The most recent analyst rating on (PGNY) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on Progyny stock, see the PGNY Stock Forecast page.
Spark’s Take on PGNY Stock
According to Spark, TipRanks’ AI Analyst, PGNY is a Outperform.
Progyny’s strong financial performance and positive earnings call sentiment are the most significant factors driving the score. The technical analysis supports a positive outlook, although the high valuation presents a potential risk. Overall, the company is well-positioned for growth, with strategic initiatives and strong client retention contributing to a favorable outlook.
To see Spark’s full report on PGNY stock, click here.
More about Progyny
Progyny, Inc. operates in the healthcare industry, specializing in fertility and family-building benefits solutions. The company offers tailored services and support for assisting individuals and employers with reproductive health and fertility management.
Average Trading Volume: 1,611,432
Technical Sentiment Signal: Buy
Current Market Cap: $2.24B
Learn more about PGNY stock on TipRanks’ Stock Analysis page.